Impact of Treatment Administration on Patient Experience in EGFR Mutated Metastatic Non-Small Cell Lung Cancer

In this segment, Dr. Devarakonda asks Dr. Singhi to address how route of administration and treatment logistics influence clinical decision making in EGFR mutated metastatic non-small cell lung cancer. Dr. Singhi introduces the concept of time toxicity, emphasizing that treatment burden extends beyond traditional adverse events and includes travel time, infusion duration, frequency of clinic visits, and coordination of supportive care.

The discussion contrasts oral therapies administered at home with intravenous and subcutaneous regimens that require in clinic administration. Differences in infusion or injection time, monitoring requirements, and visit frequency are highlighted as meaningful factors affecting quality of life, caregiver burden, and ability to maintain work or family responsibilities. The panel underscores that as survival improves and patients remain on therapy longer, administration logistics become increasingly relevant. This segment reinforces that treatment planning in EGFR mutated metastatic non-small cell lung cancer must account not only for efficacy and safety but also for patient convenience and long term sustainability.